ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit .RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA's presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.
新泽西州拉姆西和佛罗里达州博卡拉顿，2025年1月07日（全球新闻网）-- ADMA Biologics, Inc.（纳斯达克股票代码：ADMA）（"ADMA"或"公司"），是一家专注于制造、营销和开发特种生物制药的端到端商业生物制药公司，今天宣布公司管理层将在2025年1月13日至16日在加利福尼亚州旧金山举行的第43届年J.P. 摩根医疗保健会议上进行演讲。ADMA的演讲将在2025年1月13日星期一上午10:30进行。
A live audio webcast of the call will be available under "Events & Webcasts" in the investor section of the Company's website, An archived webcast will be available on the Company's website approximately two hours after the event.
电话会议的现场音频网络广播将在公司网站的投资者部分的"事件与视频"下提供，活动结束后约两小时将在公司网站上提供存档网络广播。
About ADMA Biologics, Inc. (ADMA)
关于ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit .
ADMA Biologics是一家端到端商业生物制药公司，专注于制造、营销和开发特种生物制药，用于治疗面临感染风险的免疫缺陷患者及其他某些感染性疾病风险人群。ADMA目前制造和销售三种美国食品和药物管理局（FDA）批准的血浆衍生生物制剂，用于治疗免疫缺陷及预防某些感染性疾病：BIVIGAm（人类静脉免疫球蛋白）用于治疗原发性体液免疫缺陷（PI）；ASCENIV（人类静脉免疫球蛋白 - slra 10%液体）用于治疗PI；以及NABI-Hb（人类乙型肝炎免疫球蛋白），提供增强免疫力以对抗乙型肝炎病毒。ADMA在佛罗里达州博卡拉顿的FDA许可血浆分离和纯化设施生产其免疫球蛋白产品。通过其ADMA BioCenters子公司，ADMA还作为美国FDA批准的源血浆收集者，提供其血浆用于产品的制造。ADMA的使命是制造、营销和开发针对特定患者群体的特种生物制剂和人类免疫球蛋白，以治疗和预防某些感染性疾病，并管理因基础免疫缺陷或其他医疗原因可能免疫受损的患者群体。ADMA拥有与其产品和产品候选者的各个方面相关的众多美国和外国专利。欲了解更多信息，请访问 .
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
投资者关系联系方式：
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
